AnxA10

ANXA10 (Annexin A10) is a member of the annexin family of calcium- and phospholipid-binding proteins and displays a distinctive tissue-restricted expression pattern compared with other annexin isoforms, being predominantly detected in gastric mucosa, duodenal Brunner glands, urothelium, and selected epithelial tissues^[1][2]. ANXA10 belongs to an evolutionarily conserved protein family involved in calcium signaling, membrane-associated processes, cellular differentiation, proliferation, and motility, indicating a role in the regulation of epithelial cell homeostasis and lineage-specific functions^[3][4]. Mechanistically, emerging evidence links ANXA10 to signaling pathways that influence tumor progression and cellular plasticity^[3][5]. In melanoma models, ANXA10 promotes metastatic behavior through a PKD1-SMAD6 regulatory axis, where ANXA10 stabilizes PKD1, suppresses SMAD6 expression, and thereby modulates TGF-β/SMAD-associated signaling and cell migration^[5]. Disease-associated studies further demonstrate that altered ANXA10 expression is frequently observed across gastrointestinal, hepatobiliary, pancreatic, oral, and other epithelial malignancies, supporting its value as a biomarker of tumor differentiation and disease progression^[1][6][7][8]. Compared with related annexin family members that are broadly expressed in multiple tissues, ANXA10 exhibits a more restricted distribution and cancer-type-specific expression profile, making it particularly useful for diagnostic and translational research applications^[1][2]. Although ANXA10 has been proposed as a potential therapeutic target in certain cancer contexts, current evidence primarily supports its application as a molecular marker and mechanistic research tool rather than a target with established agonists or inhibitors^[5][6].